• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predicting 5-Year Risk of RRT in Stage 3 or 4 CKD: Development and External Validation.预测 3 或 4 期 CKD 患者的 RRT 5 年风险:开发与外部验证。
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):87-94. doi: 10.2215/CJN.01290216. Epub 2016 Dec 27.
2
The Kidney Failure Risk Equation for prediction of end stage renal disease in UK primary care: An external validation and clinical impact projection cohort study.用于预测英国初级保健中终末期肾病的肾衰竭风险方程:外部验证和临床影响预测队列研究。
PLoS Med. 2019 Nov 6;16(11):e1002955. doi: 10.1371/journal.pmed.1002955. eCollection 2019 Nov.
3
Predicted risk of renal replacement therapy at arteriovenous fistula referral in chronic kidney disease.慢性肾脏病患者血管通路转运用时的肾脏替代治疗风险预测。
J Vasc Access. 2021 May;22(3):432-437. doi: 10.1177/1129729820947868. Epub 2020 Aug 8.
4
Low renal replacement therapy incidence among slowly progressing elderly chronic kidney disease patients referred to nephrology care: an observational study.转诊至肾脏病科的进展缓慢的老年慢性肾脏病患者肾替代治疗发生率较低:一项观察性研究。
BMC Nephrol. 2017 Feb 10;18(1):59. doi: 10.1186/s12882-017-0473-1.
5
Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study.日本患者慢性肾脏病进展的危险因素:来自日本慢性肾脏病队列(CKD-JAC)研究的结果。
Clin Exp Nephrol. 2017 Jun;21(3):446-456. doi: 10.1007/s10157-016-1309-1. Epub 2016 Jul 13.
6
Looking to the future: predicting renal replacement outcomes in a large community cohort with chronic kidney disease.展望未来:预测大型社区慢性肾脏病患者的肾脏替代治疗结局。
Nephrol Dial Transplant. 2015 Sep;30(9):1507-17. doi: 10.1093/ndt/gfv089. Epub 2015 May 5.
7
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用:对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
8
Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.非白蛋白尿性慢性肾脏病向终末期肾病进展的风险:CRIC(慢性肾功能不全队列)研究。
Am J Kidney Dis. 2018 Nov;72(5):653-661. doi: 10.1053/j.ajkd.2018.02.364. Epub 2018 May 18.
9
Can we predict when to start renal replacement therapy in patients with chronic kidney disease using 6 months of clinical data?我们能否使用患者 6 个月的临床数据来预测慢性肾脏病患者何时开始肾脏替代治疗?
PLoS One. 2018 Oct 4;13(10):e0204586. doi: 10.1371/journal.pone.0204586. eCollection 2018.
10
Development and validation of a model to predict 5-year risk of death without ESRD among older adults with CKD.用于预测老年慢性肾脏病患者5年非终末期肾病死亡风险模型的开发与验证
Clin J Am Soc Nephrol. 2015 Mar 6;10(3):363-71. doi: 10.2215/CJN.04650514. Epub 2015 Feb 20.

引用本文的文献

1
Twelve-Month Estimated Glomerular Filtration Rate Trajectory at the Time of Kidney Replacement Therapy Counseling Predicts Dialysis Initiation Within One Year.在进行肾脏替代治疗咨询时的12个月估计肾小球滤过率轨迹可预测一年内开始透析。
J Clin Med. 2025 Mar 14;14(6):1981. doi: 10.3390/jcm14061981.
2
The Value of Clinical Decision Support in Healthcare: A Focus on Screening and Early Detection.临床决策支持在医疗保健中的价值:聚焦筛查与早期检测
Diagnostics (Basel). 2025 Mar 6;15(5):648. doi: 10.3390/diagnostics15050648.
3
Risk-directed management of chronic kidney disease.慢性肾脏病的风险导向管理
Nat Rev Nephrol. 2025 May;21(5):287-298. doi: 10.1038/s41581-025-00931-8. Epub 2025 Jan 30.
4
Representation of multimorbidity and frailty in the development and validation of kidney failure prognostic prediction models: a systematic review.多病症和虚弱在肾衰竭预后预测模型的开发和验证中的表现:系统评价。
BMC Med. 2024 Oct 11;22(1):452. doi: 10.1186/s12916-024-03649-9.
5
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in Children and Adults: a commentary from the European Renal Best Practice (ERBP).KDIGO 2024儿童及成人慢性肾脏病评估与管理临床实践指南:欧洲肾脏最佳实践(ERBP)评论
Nephrol Dial Transplant. 2025 Feb 4;40(2):273-282. doi: 10.1093/ndt/gfae209.
6
Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners.慢性肾脏病的早期识别与管理:初级保健从业者关键作用的叙述性综述。
Adv Ther. 2024 Oct;41(10):3757-3770. doi: 10.1007/s12325-024-02957-z. Epub 2024 Aug 20.
7
Screening for chronic kidney disease: change of perspective and novel developments.慢性肾脏病的筛查:观念转变与新进展。
Curr Opin Nephrol Hypertens. 2024 Nov 1;33(6):583-592. doi: 10.1097/MNH.0000000000001016. Epub 2024 Aug 13.
8
Coronary Artery Disease in Patients Undergoing Hemodialysis: A Problem that Sounds the Alarm.接受血液透析患者的冠状动脉疾病:一个敲响警钟的问题。
Rev Cardiovasc Med. 2024 May 30;25(6):200. doi: 10.31083/j.rcm2506200. eCollection 2024 Jun.
9
A Novel Kidney Failure Prediction Model in Individuals With CKD: Impact of Serum Bilirubin Levels.慢性肾脏病患者的新型肾衰竭预测模型:血清胆红素水平的影响
J Clin Endocrinol Metab. 2025 Apr 22;110(5):1375-1383. doi: 10.1210/clinem/dgae430.
10
Derivation and Validation of a Machine Learning Model for the Prevention of Unplanned Dialysis.用于预防非计划透析的机器学习模型的推导与验证
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1098-1108. doi: 10.2215/CJN.0000000000000489. Epub 2024 May 24.

预测 3 或 4 期 CKD 患者的 RRT 5 年风险:开发与外部验证。

Predicting 5-Year Risk of RRT in Stage 3 or 4 CKD: Development and External Validation.

机构信息

Institute for Health Research and.

Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

出版信息

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):87-94. doi: 10.2215/CJN.01290216. Epub 2016 Dec 27.

DOI:10.2215/CJN.01290216
PMID:28028051
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5220646/
Abstract

BACKGROUND AND OBJECTIVES

Only a minority of patients with CKD progress to renal failure. Despite the potential benefits of risk stratification in the CKD population, risk prediction models are not routinely used. Our objective was to develop and externally validate a clinically useful and pragmatic prediction model for the 5-year risk of progression to RRT in stage 3 or 4 CKD.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a retrospective cohort design. The development cohort consisted of 22,460 Kaiser Permanente Northwest members with stage 3 or 4 CKD (baseline 2002-2008). The validation cohort consisted of 16,553 Kaiser Permanente Colorado members with stage 3-4 CKD (baseline 2006-2008). The final model included eight predictors: age, sex, eGFR, hemoglobin, proteinuria/albuminuria, systolic BP, antihypertensive medication use, and diabetes and its complications.

RESULTS

In the Northwest and Colorado cohorts, there were 737 and 360 events, and observed 5-year Kaplan-Meier risks of 4.72% (95% confidence interval [95% CI], 4.38 to 5.06) and 2.57% (95% CI, 2.30 to 2.83), respectively. Our prediction model performed extremely well in the development cohort, with a c-statistic of 0.96, an R of 79.7%, and good calibration. We had similarly good performance in the external validation cohort, with a c-statistic of 0.95, R of 81.2%, and good calibration. In the external validation cohort, the observed risk was slightly lower than the predicted risk in the highest-risk quintile. Using the top quintile of predicted risk as a cutpoint gave a sensitivity of 92.2%.

CONCLUSIONS

We developed a pragmatic prediction model and risk score for predicting the 5-year RRT risk in stage 3 and 4 CKD. This model uses variables that are typically available in routine primary care settings, and can be used to help guide important decisions such as timing of referral to nephrology and fistula placement.

摘要

背景与目的

只有少数慢性肾脏病(CKD)患者会进展为肾衰竭。尽管 CKD 人群的风险分层具有潜在益处,但风险预测模型并未常规使用。我们的目标是开发并验证一种在临床上有用且实用的预测模型,用于预测 3 或 4 期 CKD 患者在 5 年内进展为肾脏替代治疗(RRT)的风险。

设计、设置、参与者和测量方法:我们使用回顾性队列设计。该研究的开发队列包括 22460 名 Kaiser Permanente Northwest 成员,这些成员患有 3 或 4 期 CKD(基线期为 2002-2008 年)。验证队列包括 16553 名 Kaiser Permanente Colorado 成员,这些成员患有 3-4 期 CKD(基线期为 2006-2008 年)。最终模型纳入了 8 个预测因素:年龄、性别、肾小球滤过率(eGFR)、血红蛋白、蛋白尿/白蛋白尿、收缩压、降压药物使用情况以及糖尿病及其并发症。

结果

在西北和科罗拉多队列中,分别有 737 例和 360 例事件发生,观察到的 5 年 Kaplan-Meier 风险分别为 4.72%(95%置信区间[95%CI],4.38 至 5.06)和 2.57%(95%CI,2.30 至 2.83)。我们的预测模型在开发队列中表现非常出色,C 统计量为 0.96,R 为 79.7%,校准良好。在外部验证队列中,我们也获得了类似的良好表现,C 统计量为 0.95,R 为 81.2%,校准良好。在外部验证队列中,观察到的风险略低于风险最高五分位数的预测风险。使用预测风险的最高五分位数作为切点,敏感性为 92.2%。

结论

我们开发了一种实用的预测模型和风险评分,用于预测 3 或 4 期 CKD 患者在 5 年内发生 RRT 的风险。该模型使用的变量通常在常规初级保健环境中可用,可用于指导重要决策,如何时转介给肾病科和进行瘘管放置。